176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Sakiko Nagao(Okayama University Hospital), P. Harter(Kliniken Essen-Mitte), A. Leary(Institut Gustave Roussy), C. Cropet(Centre Léon Bérard), S. Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), K. Fujiwara(Saitama Medical University), Andrew Martin(Clinica Universidad de Navarra), G. Bogner(Paracelsus Medical University), I. Vergote(KU Leuven), N. Colombo(European Institute of Oncology), J. Maenpaa(Tampere University), F. Selle(Groupe Hospitalier Diaconesses Croix Saint-Simon), B. Schmalfeldt(Universität Hamburg), Giovanni Scambia(Università Cattolica del Sacro Cuore), Eva María Guerra Alia(Spanish Ovarian Cancer Research Group), C. Lefeuvre-Plesse(Centre Eugène Marquis), A. Belau(Olgahospital), A. Lortholary(Hôpital privé du Confluent), M. Gropp-Meier(Ravensburg University of Cooperative Education), Eric Pujade‐Lauraine(Arcagy Gineco), I. Ray-Coquard(Centre Léon Bérard)
Cited by 5
Abstract
Related Papers
No related papers found
Powered by citation graph analysis